Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686218 · ClinicalTrials.gov registry record · Phase 1
Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia
A Phase 1 study of Leukemia, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 3
- Study locations
NCT00686218: Completed Phase 1 study of Leukemia, sponsored by City of Hope Medical Center.
NCT00686218 is a Phase 1 study of Leukemia that has completed, run by City of Hope Medical Center. The registered enrollment target is 9 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00686218, a Phase 1 study of Leukemia, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 3
- Study locations
Study Summary
RATIONALE: Panobinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with imatinib in treating patients with previously treated chronic phase chronic myelogenous leukemia.
Conditions Studied
Interventions
- GENETIC protein expression analysis
- DRUG panobinostat
- GENETIC polymerase chain reaction
- DRUG imatinib mesylate
- GENETIC western blotting
Study Locations (3)
California
- City of Hope Medical Center - Duarte
- South Pasadena Cancer Center - South Pasadena
Washington
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
What the finished NCT00686218 record still lists
NCT00686218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00686218 reports a single indexed study location in California, Washington.
Frequently Asked Questions
What is clinical trial NCT00686218 about?
NCT00686218 is a clinical study titled "Panobinostat (LBH589) and Imatinib Mesylate in Treating Patients With Previously Treated Chronic Phase Chronic Myelogenous Leukemia". RATIONALE: Panobinostat and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with imatinib in treating patients with previously tre...
What is the current status of trial NCT00686218?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2008-05. Estimated completion is 2014-08.
What conditions does trial NCT00686218 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00686218?
The interventions under investigation include: protein expression analysis (GENETIC), panobinostat (DRUG), polymerase chain reaction (GENETIC), imatinib mesylate (DRUG), western blotting (GENETIC).
Who is sponsoring clinical trial NCT00686218?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00686218 being conducted?
This trial has 3 study locations across California, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00686218's enrollment target sits among peer trials
9 220th of 233 higher than 14 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia